Glycoengineered anti-CD20 monoclonal antibody that enhances ADCC and induces direct B-cell apoptosis.
Glycoengineered humanized type II anti-CD20 IgG1 that binds CD20 on B cells; afucosylated Fc increases affinity for FcgammaRIIIa on effector cells to enhance ADCC; also induces direct, caspase-independent B-cell apoptosis.
YES
DIRECT
Obinutuzumab binds CD20 on B cells; its afucosylated Fc strongly engages FcγRIIIa on NK cells/macrophages to trigger ADCC/ADCP, and it also induces direct, caspase‑independent apoptosis of CD20+ B cells.
Glycoengineered anti-CD20 monoclonal antibody that enhances ADCC and induces direct B-cell apoptosis.
Glycoengineered humanized type II anti-CD20 IgG1 that binds CD20 on B cells; afucosylated Fc increases affinity for FcgammaRIIIa on effector cells to enhance ADCC; also induces direct, caspase-independent B-cell apoptosis.
NO
INDIRECT
Obinutuzumab binds CD20 on B cells; its afucosylated Fc engages CD16a (FcγRIIIa) on NK cells/other effectors to trigger ADCC, killing CD20+ B cells. CD16a+ effector cells are not killed.
Glycoengineered anti-CD20 monoclonal antibody that enhances ADCC and induces direct B-cell apoptosis.
Glycoengineered humanized type II anti-CD20 IgG1 that binds CD20 on B cells; afucosylated Fc increases affinity for FcgammaRIIIa on effector cells to enhance ADCC; also induces direct, caspase-independent B-cell apoptosis.
NO
INDIRECT
Obinutuzumab targets CD20 on B cells; its afucosylated Fc engages Fcγ receptors (including CD16b) on effector cells to drive ADCC and also induces direct apoptosis of CD20+ B cells. CD16b-expressing cells are effector cells and are not killed by the drug.
First-in-human antibody-drug conjugate targeting tumor-associated MUC1 (TA-MUC1); a humanized monoclonal antibody delivers an intracellular cytotoxic payload after antigen-mediated internalization to kill TA-MUC1-positive tumor cells. Administered IV every 3 weeks in advanced/metastatic solid tumors.
DS-3939a is an ADC comprising a humanized antibody targeting tumor-associated MUC1 (TA-MUC1) linked via a cleavable peptide linker to the topoisomerase I–inhibiting payload DXd. After binding TA-MUC1 on tumor cells and internalization, lysosomal cleavage releases DXd, which stabilizes the topoisomerase I–DNA complex, causing DNA breaks, replication arrest, and apoptosis of TA-MUC1–expressing tumor cells.
YES
DIRECT
The ADC binds TA-MUC1 on tumor cells, is internalized, and its cleavable linker is degraded in lysosomes to release the DXd topoisomerase I inhibitor, which induces DNA breaks, replication arrest, and apoptosis of TA-MUC1-expressing cells.
First-in-human antibody-drug conjugate targeting tumor-associated MUC1 (TA-MUC1); a humanized monoclonal antibody delivers an intracellular cytotoxic payload after antigen-mediated internalization to kill TA-MUC1-positive tumor cells. Administered IV every 3 weeks in advanced/metastatic solid tumors.
DS-3939a is an ADC comprising a humanized antibody targeting tumor-associated MUC1 (TA-MUC1) linked via a cleavable peptide linker to the topoisomerase I–inhibiting payload DXd. After binding TA-MUC1 on tumor cells and internalization, lysosomal cleavage releases DXd, which stabilizes the topoisomerase I–DNA complex, causing DNA breaks, replication arrest, and apoptosis of TA-MUC1–expressing tumor cells.
NO
INDIRECT
DS-3939a targets TA-MUC1 on the cell surface, is internalized, and releases DXd, which inhibits DNA topoisomerase I to cause DNA damage and apoptosis. Topoisomerase I is the payload’s intracellular enzyme target, not the antigen that directs cell killing; only TA-MUC1–positive cells are selectively killed.